News | August 10, 2021
SMS Pharmaceuticals revenue grows by 44%; Profit up 235%
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Filing for WHO Emergency Use Authorisation this month
This robust growth has come despite the raging pandemic for most part of the quarter
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The company plans to enter the EU markets in FY22
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Subscribe To Our Newsletter & Stay Updated
